SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-20-118249
Filing Date
2020-10-27
Accepted
2020-10-26 19:47:08
Documents
1
Group Members
FORESITE CAPITAL FUND IV, L.P.FORESITE CAPITAL MANAGEMENT III, LLCFORESITE CAPITAL MANAGEMENT IV, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G tm2034326d1_sc13g.htm SC 13G 106002
  Complete submission text file 0001104659-20-118249.txt   107706
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Subject) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-89137 | Film No.: 201261763
SIC: 2834 Pharmaceutical Preparations

Mailing Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111 415-877-4887
Foresite Capital Fund III, L.P. (Filed by) CIK: 0001645158 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G